WO2022154542A1 - 잠재적인 호흡기바이러스 감염 개체에 인터페론-베타를 투여하는 것을 포함하는 호흡기바이러스에 대한 예방적 투여 방법 - Google Patents
잠재적인 호흡기바이러스 감염 개체에 인터페론-베타를 투여하는 것을 포함하는 호흡기바이러스에 대한 예방적 투여 방법 Download PDFInfo
- Publication number
- WO2022154542A1 WO2022154542A1 PCT/KR2022/000683 KR2022000683W WO2022154542A1 WO 2022154542 A1 WO2022154542 A1 WO 2022154542A1 KR 2022000683 W KR2022000683 W KR 2022000683W WO 2022154542 A1 WO2022154542 A1 WO 2022154542A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- coronavirus
- virus
- respiratory
- infection
- beta
- Prior art date
Links
- 102000003996 Interferon-beta Human genes 0.000 title claims abstract description 90
- 108090000467 Interferon-beta Proteins 0.000 title claims abstract description 90
- 229960001388 interferon-beta Drugs 0.000 title claims abstract description 88
- 241000700605 Viruses Species 0.000 title claims abstract description 77
- 230000000241 respiratory effect Effects 0.000 title claims abstract description 57
- 238000000034 method Methods 0.000 title claims abstract description 37
- 230000000069 prophylactic effect Effects 0.000 title abstract description 7
- 208000015181 infectious disease Diseases 0.000 claims abstract description 63
- 239000004480 active ingredient Substances 0.000 claims abstract description 13
- 241000004176 Alphacoronavirus Species 0.000 claims description 39
- 206010062106 Respiratory tract infection viral Diseases 0.000 claims description 27
- 230000002401 inhibitory effect Effects 0.000 claims description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims description 24
- 241001678559 COVID-19 virus Species 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 17
- 208000001528 Coronaviridae Infections Diseases 0.000 claims description 16
- 230000002064 post-exposure prophylaxis Effects 0.000 claims description 10
- 210000004072 lung Anatomy 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 7
- 241000712461 unidentified influenza virus Species 0.000 claims description 7
- 241000315672 SARS coronavirus Species 0.000 claims description 6
- 241000711506 Canine coronavirus Species 0.000 claims description 4
- 241000709661 Enterovirus Species 0.000 claims description 4
- 241000963676 Equine coronavirus Species 0.000 claims description 4
- 241000725579 Feline coronavirus Species 0.000 claims description 4
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims description 4
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 claims description 4
- 241001135549 Porcine epidemic diarrhea virus Species 0.000 claims description 4
- 241000156302 Porcine hemagglutinating encephalomyelitis virus Species 0.000 claims description 4
- 241000711484 Transmissible gastroenteritis virus Species 0.000 claims description 4
- 210000000621 bronchi Anatomy 0.000 claims description 4
- 210000003123 bronchiole Anatomy 0.000 claims description 4
- 210000003026 hypopharynx Anatomy 0.000 claims description 4
- 210000000867 larynx Anatomy 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 210000002850 nasal mucosa Anatomy 0.000 claims description 4
- 210000001989 nasopharynx Anatomy 0.000 claims description 4
- 210000000056 organ Anatomy 0.000 claims description 4
- 210000003300 oropharynx Anatomy 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- 210000003437 trachea Anatomy 0.000 claims description 4
- 241000711443 Bovine coronavirus Species 0.000 claims description 3
- 241000008906 Murine coronavirus Species 0.000 claims description 3
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims description 3
- 241000700584 Simplexvirus Species 0.000 claims description 3
- 241000701161 unidentified adenovirus Species 0.000 claims description 3
- 208000010470 Ageusia Diseases 0.000 claims description 2
- 206010002653 Anosmia Diseases 0.000 claims description 2
- 241000008921 Avian coronavirus Species 0.000 claims description 2
- 241000008922 Beluga Whale coronavirus SW1 Species 0.000 claims description 2
- 241000124740 Bocaparvovirus Species 0.000 claims description 2
- 206010010741 Conjunctivitis Diseases 0.000 claims description 2
- 206010011224 Cough Diseases 0.000 claims description 2
- 241000701022 Cytomegalovirus Species 0.000 claims description 2
- 206010012735 Diarrhoea Diseases 0.000 claims description 2
- 208000010201 Exanthema Diseases 0.000 claims description 2
- 206010019233 Headaches Diseases 0.000 claims description 2
- 201000005505 Measles Diseases 0.000 claims description 2
- 241000351643 Metapneumovirus Species 0.000 claims description 2
- 241000008902 Miniopterus bat coronavirus 1 Species 0.000 claims description 2
- 241000008903 Miniopterus bat coronavirus HKU8 Species 0.000 claims description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 claims description 2
- 241000150452 Orthohantavirus Species 0.000 claims description 2
- 201000007100 Pharyngitis Diseases 0.000 claims description 2
- 241000008909 Pipistrellus bat coronavirus HKU5 Species 0.000 claims description 2
- 206010037660 Pyrexia Diseases 0.000 claims description 2
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 2
- 241000008907 Rousettus bat coronavirus HKU9 Species 0.000 claims description 2
- 241000004179 Scotophilus bat coronavirus 512 Species 0.000 claims description 2
- 241000282898 Sus scrofa Species 0.000 claims description 2
- 241000947555 Thrush coronavirus HKU12 Species 0.000 claims description 2
- 241000008908 Tylonycteris bat coronavirus HKU4 Species 0.000 claims description 2
- 235000019666 ageusia Nutrition 0.000 claims description 2
- 208000027499 body ache Diseases 0.000 claims description 2
- 238000002845 discoloration Methods 0.000 claims description 2
- 208000017574 dry cough Diseases 0.000 claims description 2
- 201000005884 exanthem Diseases 0.000 claims description 2
- 206010016256 fatigue Diseases 0.000 claims description 2
- 231100000869 headache Toxicity 0.000 claims description 2
- 206010037844 rash Diseases 0.000 claims description 2
- 231100000046 skin rash Toxicity 0.000 claims description 2
- 210000003371 toe Anatomy 0.000 claims description 2
- 241000711573 Coronaviridae Species 0.000 claims 6
- 208000005577 Gastroenteritis Diseases 0.000 claims 1
- 241001504477 Pycnonotidae Species 0.000 claims 1
- 241000228636 Rhinolophus Species 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 230000009385 viral infection Effects 0.000 abstract description 8
- 230000029058 respiratory gaseous exchange Effects 0.000 abstract description 3
- 230000000452 restraining effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 48
- 230000000694 effects Effects 0.000 description 22
- 238000003556 assay Methods 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 241000282412 Homo Species 0.000 description 12
- RWWYLEGWBNMMLJ-MEUHYHILSA-N remdesivir Drugs C([C@@H]1[C@H]([C@@H](O)[C@@](C#N)(O1)C=1N2N=CN=C(N)C2=CC=1)O)OP(=O)(N[C@@H](C)C(=O)OCC(CC)CC)OC1=CC=CC=C1 RWWYLEGWBNMMLJ-MEUHYHILSA-N 0.000 description 10
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 230000003449 preventive effect Effects 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 8
- 238000011529 RT qPCR Methods 0.000 description 7
- 231100000516 lung damage Toxicity 0.000 description 7
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 210000002345 respiratory system Anatomy 0.000 description 6
- 208000025721 COVID-19 Diseases 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 206010022000 influenza Diseases 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 229920000936 Agarose Polymers 0.000 description 4
- 208000004852 Lung Injury Diseases 0.000 description 4
- 206010069363 Traumatic lung injury Diseases 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 210000003128 head Anatomy 0.000 description 4
- 231100000515 lung injury Toxicity 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000699800 Cricetinae Species 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 3
- 229920002472 Starch Chemical class 0.000 description 3
- 239000001913 cellulose Chemical class 0.000 description 3
- 229920002678 cellulose Chemical class 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000008904 Betacoronavirus Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- -1 and preferably Proteins 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 210000003501 vero cell Anatomy 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241001218594 Bulbul coronavirus HKU11 Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241001461743 Deltacoronavirus Species 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 101150013191 E gene Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000008920 Gammacoronavirus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 101001054334 Homo sapiens Interferon beta Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000699673 Mesocricetus auratus Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000947552 Munia coronavirus HKU13 Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000004178 Rhinolophus bat coronavirus HKU2 Species 0.000 description 1
- 101100316897 Severe acute respiratory syndrome coronavirus 2 E gene Proteins 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 102000034238 globular proteins Human genes 0.000 description 1
- 108091005896 globular proteins Proteins 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000008202 granule composition Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 238000002941 microtiter virus yield reduction assay Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 208000026425 severe pneumonia Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008107 starch Chemical class 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
Definitions
- the present invention relates to a prophylactic administration method for respiratory viruses comprising administering interferon-beta to a potentially potentially respiratory virus-infected individual, and more particularly, interferon-beta as an active ingredient, interferon-beta
- a prophylactic administration method for respiratory viruses comprising administering interferon-beta to a potentially potentially respiratory virus-infected individual, and more particularly, interferon-beta as an active ingredient, interferon-beta
- a prophylactic administration method for respiratory viruses comprising administering interferon-beta to a potentially potentially respiratory virus-infected individual, and more particularly, interferon-beta as an active ingredient, interferon-beta
- Respiratory diseases caused by viral respiratory infections are the most common diseases, accounting for about half of all infectious diseases. Respiratory virus infection mainly occurs in children and elderly immunocompromised patients, and the most well known representative respiratory infection viruses are adenovirus, parainfluenza virus (PIV), and RS virus (respiratory syncytial). virus, RSV), rhinovirus, and coronavirus.
- PIV parainfluenza virus
- RS virus respiratory syncytial
- coronavirus is divided into four genera, alpha and beta infect humans and animals, and gamma and delta infect animals only. There are six types of coronavirus that can infect humans. Of these, four (229E, OC43, NL63, HKU1) are known to be the viruses that cause colds, and the other two are viruses that can cause severe pneumonia in humans, and Middle East Respiratory Syndrome Coronavirus (MERS-CoV). ) and SARS coronavirus (Severe Acute Respiratory Syndrome Coronavirus, SARS-CoV).
- novel respiratory virus which was first identified in a pneumonia patient in Wuhan City, Hubei province, China in December 2019, had a wide spread and had a serious impact on the medical system.
- the novel coronavirus that occurred in 2019 was identified as a family different from the existing MERS-CoV and SARS-CoV viruses, and was identified as the seventh coronavirus species that infects humans.
- the virus was named 'SARS-CoV-2' and is the cause of the disease called 'Coronavirus Disease 2019 (COVID-19)'.
- Patent Document 1 Korean Patent Publication No. 10-2018201
- Patent Document 2 Korean Patent Publication No. 10-1800366
- Patent Document 3 Korean Patent Publication No. 10-2019-0063512
- Non-Patent Document 1 Zhu, Na, et al. "A novel coronavirus from patients with pneumonia in China, 2019.” New England Journal of Medicine (2020).
- Another object of the present invention is to provide a pharmaceutical composition for inhibiting self-replicating infection of a respiratory virus in an individual exposed to a potential respiratory viral infection consisting of interferon-beta.
- Another object of the present invention is to provide a pharmaceutical composition for inhibiting self-replicating infection of a respiratory virus in an individual exposed to a potential respiratory viral infection consisting essentially of interferon-beta.
- Another object of the present invention is a post-exposure prophylaxis (PEP) method for protecting an individual from self-replicating infection by a respiratory virus after exposure to a potential respiratory viral infection, wherein the method comprises a prophylactically effective amount of interferon- To provide a method, characterized in that beta is administered to a subject.
- PEP post-exposure prophylaxis
- Another object of the present invention is to provide a method for protecting an individual from self-replicating infection by a respiratory virus comprising administering to the individual a prophylactically effective amount of interferon-beta after exposure to a potential respiratory viral infection.
- Another object of the present invention is to provide the use of interferon-beta for the manufacture of a preparation for inhibiting self-replicating infection of a respiratory virus in an individual exposed to a potential respiratory viral infection.
- Another object of the present invention is to provide a method of inhibiting self-replicating infection of a respiratory virus in an individual exposed to a potential respiratory viral infection, comprising administering to an individual in need thereof an effective amount of a composition comprising interferon-beta as an active ingredient.
- the present invention provides a pharmaceutical composition for inhibiting self-replicating infection of a respiratory virus in an individual exposed to a potential respiratory viral infection comprising interferon-beta as an active ingredient.
- the present invention provides a pharmaceutical composition for inhibiting self-replicating infection of a respiratory virus in an individual exposed to a potential respiratory viral infection consisting of interferon-beta.
- the present invention provides a pharmaceutical composition for inhibiting self-replicating infection of a respiratory virus in an individual exposed to a potential respiratory viral infection consisting essentially of interferon-beta.
- the present invention provides a post-exposure prophylaxis (PEP) method for protecting an individual from self-replicating infection by a respiratory virus after exposure to a potential respiratory viral infection, said method comprising: Provided is a method comprising administering interferon-beta to the subject.
- PEP post-exposure prophylaxis
- the present invention provides a method for protecting an individual from self-replicating infection by a respiratory virus comprising administering to the individual a prophylactically effective amount of interferon-beta after exposure to a potential respiratory viral infection.
- the present invention provides the use of interferon-beta for the manufacture of a preparation for inhibiting self-replicating infection of a respiratory virus in an individual exposed to a potential respiratory viral infection.
- the present invention relates to a respiratory virus in an individual exposed to a potential respiratory viral infection, comprising administering to an individual in need thereof an effective amount of a composition comprising interferon-beta as an active ingredient.
- a method for inhibiting self-replicating infection comprising administering to an individual in need thereof an effective amount of a composition comprising interferon-beta as an active ingredient.
- the present invention provides a pharmaceutical composition for inhibiting self-replicating infection of a respiratory virus in an individual exposed to a potential respiratory viral infection comprising interferon-beta as an active ingredient.
- Interferon-beta is a globular protein with 5 alpha helices, the size of which is 22 kDa, and has antiviral activity, cell growth inhibition or antiproliferative activity, lymphocyte cytotoxicity enhancing activity, immunomodulatory activity, target cell differentiation induction or inhibitory activity, Cancer, autoimmune disorders, viral infection, HIV and other immunological activities such as macrophage activation activity, cytokine production increase activity, cytotoxic T cell effect increase activity, natural killing cell increase activity, etc. There are reports that it is effective in treating related diseases, hepatitis C, rheumatoid arthritis, etc.
- Interferon-beta of the present invention may be native (wild-type) or mutant interferon-beta, and preferably, interferon-beta (interferon-beta polypeptide or interferon-beta protein) of the present invention is 27 of wild-type interferon-beta.
- the arginine (R27) region is mutated (R27T) to threonine, and may be a polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 1.
- Interferon-beta of the present invention may have sugar chains bound to two positions of amino acids 25 and 80 of SEQ ID NO: 1, and should be understood as a polypeptide having interferon-beta activity.
- the interferon-beta of the present invention represents human interferon-beta.
- interferon-beta is administered in such a way that it directly reaches the cells infected with or potentially infected with the coronavirus. More specifically, interferon-beta comes into contact with respiratory virus-infected or potentially infected cells by administration by inhalation, and interferon-beta reaches the respiratory virus-infected or potentially infected cells, resulting in interferon beta receptors in the cells. It functions in a way that is combined with
- Administration by inhalation is administered through the oral cavity or nasal cavity due to the structure of the respiratory tract, for example, interferon-beta or a carrier containing interferon-beta in a liquid, aerosol, or gaseous state such that it is in contact with respiratory cells through the oral cavity or nasal cavity. It may be administered by injection or infusion.
- the respiratory system refers to the organs through which breathing is made as a whole, and refers to each organ that starts from the nose and mouth and leads to the airways and the lungs.
- the respiratory tract in the present invention is a nasal mucosa, nasopharynx, oropharynx, laryngopharynx, larynx, trachea, bronchi, bronchiole, lung.
- respiratory viruses include adenovirus, avian influenza virus, bocavirus, coronavirus, cytomegalovirus, Hantavirus, herpes simplex virus.
- Herpes Simplex Virus, Influenza Virus, Measles, Metapneumovirus, Parainfluenza Virus, Respiratory Syncytial Virus, Rhinovirus, Varicella-zoster virus (Varicella-zoster Virus) may be selected from the group consisting of.
- the respiratory virus of the present invention is a coronavirus.
- the subject may be an individual who is not infected with the coronavirus or is at an early stage of infection with the coronavirus.
- Individuals who are clinically or regulatoryly at risk of exposure to coronavirus e.g., individuals who have been in close contact with or have been in close contact with individuals infected with coronavirus, individuals for whom quarantine is recommended or compulsory, or those who are engaged in coronavirus treatment medical personnel
- asymptomatic transmission individuals infected with coronavirus and individuals with initial infection of coronavirus
- the coronavirus-infected individual can be easily identified by those skilled in the art using known coronavirus diagnostic kits.
- the subject may be a person who is not infected with the coronavirus or is at an early stage of infection with the coronavirus. Therefore, the present invention can inhibit or reduce the spread of the virus to the surroundings while an individual infected with the coronavirus is asymptomatic.
- PrEP pre-exposure prophylaxis
- PEP post-exposure prophylaxis
- the subject at the initial stage of coronavirus infection is one selected from the group consisting of fever, dry cough, fatigue, body aches, sore throat, diarrhea, conjunctivitis, headache, loss of taste or smell, skin rash, discoloration of fingers or toes. It may be an individual with no symptoms.
- the coronavirus is i) 229E, NL63 that infects humans or porcine epidemic diarrhea virus (PEDV) that does not infect humans, (swine) transmissible gastroenteritis virus (TGEV), canine corona Canine coronavirus (CCoV), feline coronavirus (FCoV), Miniopterus bat coronavirus 1, Miniopterus bat coronavirus HKU8, Rhinolophus bat coronavirus HKU2, Scotophilus bat coronavirus 512 alpha-coronavirus; ii) OC43, HKU1, SARS-CoV, MERS-CoV, SARS-CoV-2 that infects humans, or porcine hemagglutinating encephalomyelitis virus (PHEV) that does not infect humans, bovine coronavirus: BCoV), equine coronavirus (EqCoV), murine coronavirus (MuCoV), Tylonycteris bat coronavirus HKU4, Pi
- the self-replicating infection indicates that the coronavirus replicates in respiratory cells of the subject and infects surrounding cells.
- the life cycle of the coronavirus is well known.
- the present invention provides a post-exposure prophylaxis (PEP) method for protecting an individual from self-replicating infection by a respiratory virus after exposure to a potential respiratory viral infection, the method comprising administering a prophylactically effective amount of interferon-beta to the individual It provides a method characterized in that it is.
- PEP post-exposure prophylaxis
- the present invention also provides a method of protecting an individual from self-replicating infection by a respiratory virus comprising administering to the individual a prophylactically effective amount of interferon-beta after exposure to a potential respiratory viral infection.
- a method for protecting an individual from self-replicating infection caused by a coronavirus further comprising concurrently or sequentially administering a known coronavirus therapeutic agent during clinical trials or during clinical trials.
- the administration of the coronavirus therapeutic agent may be oral, inhalational, intraperitoneal or intravenous administration.
- the pharmaceutical composition according to the present invention may contain the coronavirus therapeutic agent of the present invention alone or may additionally contain one or more pharmaceutically acceptable carriers, excipients or diluents.
- the pharmaceutically acceptable carrier may further include, for example, a carrier for oral administration or a carrier for parenteral administration.
- Carriers for oral administration may include lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like.
- the carrier for parenteral administration may include water, a suitable oil, saline, aqueous glucose and glycol, and the like, and may further include a stabilizer and a preservative.
- Suitable stabilizers include antioxidants such as sodium hydrogen sulfite, sodium sulfite or ascorbic acid.
- Suitable preservatives include benzalkonium chloride, methyl- or propyl-paraben and chlorobutanol.
- those known in the art may be referred to.
- composition of the present invention preferably includes an active ingredient: a pharmaceutically acceptable carrier in a weight ratio of 0.1 - 99.9: 99.9 - 0.1, but is not limited thereto.
- the pharmaceutical composition of the present invention may be administered to mammals including humans by any method.
- it may be administered orally or parenterally, and may be formulated as a formulation for oral administration or parenteral administration depending on the route of administration.
- the composition of the present invention may be formulated as a powder, granule, tablet, pill, dragee, capsule, liquid, gel, syrup, slurry, suspension, etc. using methods known in the art.
- oral preparations can be obtained by mixing the active ingredient with a solid excipient, pulverizing it, adding a suitable adjuvant, and processing it into a granule mixture to obtain tablets or dragees.
- excipients include sugars including lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol and maltitol, and starches, including corn starch, wheat starch, rice starch and potato starch, cellulose, Cellulose, including methyl cellulose, sodium carboxymethylcellulose and hydroxypropylmethyl-cellulose, and the like, fillers such as gelatin, polyvinylpyrrolidone, and the like may be included. In addition, cross-linked polyvinylpyrrolidone, agar, alginic acid or sodium alginate may be added as a disintegrant if necessary. Furthermore, the pharmaceutical composition of the present invention may further include an anti-aggregating agent, a lubricant, a wetting agent, a flavoring agent, an emulsifying agent, and an antiseptic agent.
- sugars including lactose, dextrose, sucrose, sorbitol, manni
- Formulations for parenteral administration may be formulated in the form of injections, creams, lotions, external ointments, oils, moisturizers, gels, aerosols and nasal inhalants by methods known in the art. These formulations are described in formulary commonly known in all pharmaceutical chemistry.
- the total effective amount of the composition of the present invention may be administered to a patient as a single dose, or may be administered by a fractionated treatment protocol in which multiple doses are administered for a long period of time.
- the pharmaceutical composition of the present invention may vary the content of the active ingredient depending on the severity of the disease.
- the preferred total dose of the pharmaceutical composition of the present invention may be about 0.01 to 10,000 mg, most preferably 0.1 to 500 mg per patient body weight per day.
- the dosage of the pharmaceutical composition is determined by considering various factors such as the formulation method, administration route and number of treatments, as well as the patient's age, weight, health status, sex, severity of disease, diet and excretion rate, etc., the effective dosage for the patient is determined.
- the pharmaceutical composition according to the present invention is not particularly limited in its formulation, administration route and administration method as long as the effect of the present invention is exhibited.
- the present invention provides the use of interferon-beta for the manufacture of a preparation for inhibiting self-replicating infection of a respiratory virus in a subject exposed to a potential respiratory viral infection.
- the present invention provides a method for inhibiting self-replicating infection of a respiratory virus in an individual exposed to a potential respiratory viral infection, comprising administering to an individual in need thereof an effective amount of a composition comprising interferon-beta as an active ingredient.
- the 'effective amount' of the present invention refers to an amount that exhibits the effect of improving, treating, preventing, detecting, diagnosing, or inhibiting or reducing the disease when administered to an individual, and the 'individual' is an animal, preferably may be mammals, particularly animals, including humans, and may be cells, tissues, organs, etc. derived from animals. The subject may be a patient in need of the effect.
- the term “comprising” is used synonymously with “including” or “characterized by”, and in a composition or method according to the present invention, specifically referring to It does not exclude additional components or method steps that are not listed. Also, the term “consisting of” means excluding additional elements, steps, or components not otherwise described. The term “essentially consisting of” means that, in the scope of a composition or method, it may include substances or steps that do not materially affect its basic properties in addition to the substances or steps described.
- interferon-beta is administered to the nasal mucosa, nasopharynx, oropharynx, laryngopharynx, larynx, trachea, bronchi, and bronchiole. , can effectively inhibit self-replicating infection of coronavirus in individuals exposed to potential coronavirus infection by inhalation to the respiratory tract, such as lungs.
- FIG. 1A and 1B are results confirming the inhibitory effect of interferon on coronavirus infection by treating cells with interferon beta before (FIG. 1A) or after infection (FIG. 1B) of SARS-CoV-2 infection.
- FIGS. 1A and 1B are results of quantitative analysis of the results of FIGS. 1A and 1B.
- 5 is a schematic sequence of experiments for analyzing the preventive effect of interferon-beta before exposure to coronavirus Wuhan strain or delta mutation.
- FIG. 7 is a schematic sequence of experiments for analyzing the preventive or therapeutic effect of interferon-beta after exposure to the coronavirus Wuhan strain or delta mutation.
- RT-qPCR was performed by extracting RNA after infection with Vero E6 cells and then interferon-beta treatment.
- the processing conditions are as follows.
- Vero cells were grown in DMEM media with a medium containing 2% heat-inactivated FBS and 2mM L-glutamine and seeded at 5 x 10 5 cells/well in 6-wells at 37°C to maintain about 80% confluency. 5% CO 2 Incubated in an incubator.
- SARS-CoV-2 stock was first infected with about 2 x 10 6 plaque-forming units (PFU/mL) and then treated with ABN101.
- PFU/mL plaque-forming units
- the concentration of ABN101 was After treating each star first, it was tested by infecting the SARS-CoV-2 stock.
- interferon-beta (ABN101, R27T interferon-beta) was diluted to 5000 IU/mL, 1,000 IU/mL, 2,000 IU/mL, and 5,000 IU/mL by concentration. This was cultured for 3 days at 37° C., 5% CO 2 in an incubator, and then the culture supernatant was recovered, respectively. Each supernatant was filtered to remove cells, and total RNA was isolated.
- the SARS-CoV-2 virus was reduced by interferon-beta treatment through quantitative real-time RT-qPCR using the isolated RNA as a template and using a primer that can specifically detect the SARS-CoV-2 E gene. It was checked whether or not
- the primer sequences and probes for detecting the E gene of SARS-CoV-2 used in this experiment are as follows.
- Probe sequence 5'-ATATTGCAGCAGTACGCACACA-3' (SEQ ID NO: 2)
- Primer-1 sequence 5'-ACAGGTACGTTAATAGTTAATAGCGT-3' (SEQ ID NO: 3)
- Primer-2 sequence 5'-ATATTGCAGCAGTACGCACACA-3' (SEQ ID NO: 4)
- interferon-beta (ABN101, R27T interferon-beta) was diluted to 5000 IU/mL, 1,000 IU/mL, 2,000 IU/mL, 5,000 IU/mL by concentration and treated for 24 hours, then the culture medium was removed, After SARS-CoV-2 was treated with Vero E6 cells for 1 hour and 30 minutes to infect the cells, the infected virus was completely removed and 3 ml of culture media was added. This was cultured in an incubator at 37° C., 5% CO 2 , and on the second day, each culture supernatant was recovered, filtered through a filter, cells were removed, and total RNA was isolated. The RT-qPCR experiment was performed in the same way as the pre-infection experiment.
- FIGS. 2a and 2b The quantitative analysis is shown in FIGS. 2a and 2b, and it was confirmed that the EC50 of ABN101 for SARS-CoV-2 was 121.5 pM (pre-infection) and 72.3 pM (post-infection), respectively.
- Example 2 Comparison of the effect of inhibiting coronavirus infection with remdesivir
- the cells were overlaid with agarose and stained with crystal violet to analyze viral plaques to determine how many cells were infected with the virus.
- Vero cells were grown in DMEM media with a medium containing 2% heat-inactivated FBS and 2mM L-glutamine and seeded at 5 x 10 5 cells/well in 6-wells to maintain about 80% confluency at 37°C 5 % CO 2 Incubated in an incubator. The next day after seeding, SARS-CoV-2 stock was treated with about 2 x 10 6 plaque-forming units (PFU/mL).
- Remdesivir was prepared by dissolving in DMSO, and Mock-1 and Mock-2 were prepared as the measurement standard was to control substances containing DMSO.
- the treatment materials for Mock-1 and Mock-2 are as follows.
- Mock-1 culture media only after virus infection
- Mock-2 culture media + DMSO after virus infection
- the left side of FIG. 3 is the result of the plaque assay, and when interferon-beta was treated with pre-infection and post-infection, respectively (lower left), the treated cells were treated with remdesivir (upper left), compared to the case where the infected cells were not confirmed. ), it was found that the virus infection was not significantly inhibited.
- the EC50 of Remdesivir is known to be 74 nM, it was confirmed that the EC50 of interferon-beta showed good efficacy at a concentration about 600 times lower than that.
- FIG. 3 The right side of FIG. 3 is the result of real-time quantitative RT-qPCR, and the experiment was performed in the same manner as in FIG. 1 .
- the efficacy of interferon-beta was superior to the EC50 of Remdesivir, as the difference in Ct value increased.
- Example 3 Inhibition of lung damage caused by coronavirus infection of interferon-beta in a hamster infection model
- SARS-CoV-2 Infection In order to determine the degree of lung damage, a 6-week-old male Syrian Hamster was prepared and the virus was infected at 100 PFU/head by nasal administration. Immediately after infection (0 day post-injection (d.p.i.)), 2 days after (2 d.p.i), and 4 days after (4 d.p.i) interferon-beta (ABN101) was treated with 0.15 MIU/head and 1 MIU/head, respectively. After that, the degree of lung tissue damage was evaluated.
- the control group was administered with virus only (control, virus only), and for the experimental group, interferon-beta was administered to the respiratory tract in an amount of 0.15MIU (million IU) and 1MIU through nasal administration, respectively.
- the degree of lung damage was evaluated by a third-party expert with a veterinarian license, and after sacrificing a hamster, whole lungs were collected, and the lung number of the virus-only group and the interferon-beta-administered group were numbered and blinded to measure the degree of damage. This is a lung injury score scale on a scale of 0-10, and the total area of the lung damage was measured up to 10 points, and the normal level was evaluated by measuring it up to 0 points.
- Vero E6 cells were treated with interferon-beta and then removed, and then, Wuhan or delta mutant coronavirus was analyzed by plaque analysis after infection.
- the cells were overlaid with agarose and stained with crystal violet to analyze virus plaques to determine how many cells were infected with the virus.
- Vero E6 cells were grown in Complete DMEM media (10% FBS), and Vero E6 cells were seeded in 12-wells and cultured in a 37°C 5% CO 2 incubator to maintain about 80% confluence.
- SARS-CoV-2 stock (Wuhan strain or delta variant) was treated with about 100 plaque-forming units (PFU/mL) to measure the prophylactic effect.
- ABN101 was administered at different concentrations of 25 IU/mL, 50 IU/mL, 100 IU/mL, 250 IU/mL, 500 IU/mL, 1,000 IU/mL, 2,500 IU/mL, and 5,000 IU/mL, 10,000 IU/mL and 25,000 IU/mL were treated, and ABN101 was removed after 24 hours. Thereafter, the Wuhan strain or delta variant of SARS-CoV-2 was treated in Vero E6 cells for 1 hour to infect the cells, and after completely removing the infected virus, incubated in new culture media for 72 hours. , plaque assay was performed.
- SARS-CoV-2 (Wuhan) SARS-CoV-2 (Delta) Concentration (IU/mL) Plaque No. Concentration (IU/mL) Plaque No. 25000 0 25000 0 10000 0 10000 0 5000 0 5000 0 2500 0 2500 One 1000 One 1000 One 500 2 500 3 250 2 250 7 100 8 100 23 50 11 50 23 25 23 25 26 0 43 0 28 Non-Infection 0 Non-Infection 0
- Example 5 Interferon-beta corona virus Wuhan strain or delta mutation (delta) after exposure to preventive or therapeutic effect
- Vero E6 cells were infected with Wuhan or delta mutant coronavirus and then treated with interferon-beta by concentration and analyzed by plaque assay.
- the cells were overlaid with agarose and stained with crystal violet to analyze virus plaques to determine how many cells were infected with the virus.
- Vero E6 cells were grown in Complete DMEM media (10% FBS), and Vero E6 cells were seeded in 12-wells and cultured in a 37°C 5% CO 2 incubator to maintain about 80% confluence.
- SARS-CoV-2 stock (Wuhan strain or delta variant) was treated with about 100 plaque-forming units (PFU/mL) to measure the therapeutic effect.
- the Wuhan strain or delta variant of SARS-CoV-2 was treated in Vero E6 cells for 1 hour to infect the cells, and after completely removing the infected virus, ABN101 was administered at 25 IU/concentration. mL, 50 IU/mL, 100 IU/mL, 250 IU/mL, 500 IU/mL, 1,000 IU/mL, 2,500 IU/mL, 5,000 IU/mL, 10,000 IU/mL, and 25,000 IU/mL for 72 hours. After treatment, the media was recovered, and the virus titration was measured to confirm the efficacy of inhibiting infection.
- FIG. 7 A flowchart of this experiment is shown in FIG. 7 .
- the infection inhibition efficacy of more than 95% at 500 IU/mL or more for both coronavirus strains was confirmed.
- the efficacy of ABN101 to inhibit infection was found to have an EC50 activity of 59.11 IU/mL against the Wuhan strain and an EC50 activity of 25 IU/mL against the Delta strain.
- SARS-CoV-2 (Wuhan) SARS-CoV-2 (Delta) Concentration (IU/mL) Titration (PFU/mL) Concentration (IU/mL) Titration (PFU/mL) 25000 0.00 25000 1.00 x 10 2 10000 0.00 10000 1.10 x 10 2 5000 0.00 5000 1.80 x 10 2 2500 3.70 x 10 2 2500 3.10 x 10 4 1000 1.80 x 10 4 1000 3.00 x 10 3 500 3.50 x 10 5 500 3.00 x 10 4 250 8.00 x 10 5 250 9.00 x 10 4 100 1.90 x 10 6 100 1.30 x 10 5 50 3.20 x 10 6 50 1.80 x 10 5 25 3.00 x 10 6 25 4.00 x 10 5 0 6.00 x 10 5 0 8.00 x 10 5
- Vero E6 cells were treated with interferon-beta and then removed, and influenza virus (H1N1/A/PR8) was analyzed by plaque assay after infection.
- the cells were overlaid with agarose and stained with crystal violet to analyze virus plaques to determine how many cells were infected with the virus.
- MDCK cells were grown in Complete DMEM media (10% FBS), and MDCK cells were seeded in 12-wells and cultured in a 37°C 5% CO 2 incubator to maintain about 80% confluence.
- Influenza virus stock H1N1/A/PR8 was treated with about 100 plaque-forming units (PFU/mL) to measure the prophylactic effect.
- ABN101 was administered at different concentrations of 25 IU/mL, 50 IU/mL, 100 IU/mL, 250 IU/mL, 500 IU/mL, 1,000 IU/mL, 2,500 IU/mL, and 5,000 IU/mL, 10,000 IU/mL and 25,000 IU/mL were treated, and ABN101 was removed after 24 hours. Thereafter, the influenza virus (H1N1/A/PR8) was treated with MDCK cells for 1 hour to infect the cells, and after completely removing the infected virus, incubated in new culture media for 72 hours, plaque assay was performed.
- influenza virus H1N1/A/PR8
- the ABN101 treatment group showed an influenza infection prevention effect of 20% or more compared to the untreated group.
- interferon-beta is administered to the nasal mucosa, nasopharynx, oropharynx, laryngopharynx, larynx, trachea, bronchi, and bronchiole. , can effectively inhibit self-replicating infection of coronavirus in individuals exposed to potential coronavirus infection by inhalation to the respiratory tract, such as lungs.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Group | 바이러스투여 (PFU/head) | 투여 시점 | 폐손상점수 |
Virus only | 100 | - | 3.8±0.98 |
ABN101 0.15 MIU Nasal 투여 |
100 | 0, 2, 4 DPI | 3.5±1.69 |
ABN101 1 MIU Nasal 투여 |
100 | 0, 2, 4 DPI | 3.1±1.63 |
SARS-CoV-2 (Wuhan) | SARS-CoV-2 (Delta) | ||
Concentration (IU/mL) | Plaque No. | Concentration (IU/mL) | Plaque No. |
25000 | 0 | 25000 | 0 |
10000 | 0 | 10000 | 0 |
5000 | 0 | 5000 | 0 |
2500 | 0 | 2500 | 1 |
1000 | 1 | 1000 | 1 |
500 | 2 | 500 | 3 |
250 | 2 | 250 | 7 |
100 | 8 | 100 | 23 |
50 | 11 | 50 | 23 |
25 | 23 | 25 | 26 |
0 | 43 | 0 | 28 |
Non-Infection | 0 | Non-Infection | 0 |
SARS-CoV-2 (Wuhan) | SARS-CoV-2 (Delta) | ||
Concentration (IU/mL) | Titration (PFU/mL) | Concentration (IU/mL) | Titration (PFU/mL) |
25000 | 0.00 | 25000 | 1.00 x 102 |
10000 | 0.00 | 10000 | 1.10 x 102 |
5000 | 0.00 | 5000 | 1.80 x 102 |
2500 | 3.70 x 102 | 2500 | 3.10 x 104 |
1000 | 1.80 x 104 | 1000 | 3.00 x 103 |
500 | 3.50 x 105 | 500 | 3.00 x 104 |
250 | 8.00 x 105 | 250 | 9.00 x 104 |
100 | 1.90 x 106 | 100 | 1.30 x 105 |
50 | 3.20 x 106 | 50 | 1.80 x 105 |
25 | 3.00 x 106 | 25 | 4.00 x 105 |
0 | 6.00 x 105 | 0 | 8.00 x 105 |
Claims (14)
- 인터페론-베타를 유효성분으로 포함하는 잠재적인 호흡기바이러스 감염에 노출된 개체에서의 호흡기바이러스의 자가 복제 감염 억제용 약학적 조성물.
- 제1항에 있어서, 상기 인터페론-베타는 서열번호 1의 아미노산 서열을 가지는 것을 특징으로 하는 약학적 조성물.
- 제1항에 있어서, 상기 인터페론-베타는 흡입에 의한 투여에 의해서 투여되는 것을 특징으로 하는 약학적 조성물.
- 제3항에 있어서, 상기 흡입에 의한 투여는 흡입에 의해서, 호흡기 세포에 접촉하여 투여되는 것을 특징으로 하는 약학적 조성물.
- 제4항에 있어서, 상기 호흡기는 비강 점막, 비강 인두 (nasopharynx), 구강 인두 (oropharynx), 후두 인두 (laryngopharynx), 후두, 기관 (trachea), 기관지 (bronchi), 세기관지 (bronchiole), 폐 (lung)인 것을 특징으로 하는 약학적 조성물.
- 제1항에 있어서, 상기 호흡기바이러스는 코로나바이러스이며, 상기 개체는 코로나바이러스에 감염되지 않았거나 코로나바이러스 감염 초기인 개체인 것을 특징으로 하는 약학적 조성물.
- 제6항에 있어서, 상기 코로나바이러스 감염 초기인 개체는 발열, 마른기침, 피로감, 몸살, 인후통, 설사, 결막염, 두통, 미각 또는 후각 상실, 피부 발진, 손가락 또는 발가락 변색으로 이루어진 군에서 선택된 어느 하나의 코로나바이러스 감염 증상이 나타나지 않은 개체인 것을 특징으로 하는 약학적 조성물.
- 제1항에 있어서, 상기 호흡기 바이러스는 아데노바이러스 (Adenovirus), 조류 독감 바이러스 (Avian Influenza Virus), 보카바이러스 (Bocavirus), 코로나바이러스 (Coronavirus), 사이토메갈로바이러스 (Cytomegalovirus), 한타바이러스 (Hantavirus), 헤르페스 심플렉스 바이러스 (Herpes Simplex Virus), 독감 바이러스 (Influenza Virus), 홍역 바이러스 (Measles), 메타뉴모바이러스 (Metapneumovirus), 파라인플루엔자 바이러스 (Parainfluenza Virus), 호흡기 세포융합 바이러스 (Respiratory Syncytial Virus), 리노바이러스 (Rhinovirus), 바리셀라-조스터 바이러스 (Varicella-zoster Virus)로 이루어진 군에서 선택된 것임을 특징으로 하는 약학적 조성물.
- 제8항에 있어서, 상기 코로나바이러스는 229E, NL63, OC43, HKU1, SARS-CoV, MERS-CoV, SARS-CoV-2, 돼지 유행성 설사 바이러스(porcine epidemic diarrhea virus : PEDV), (돼지) 전염성 위장염 바이러스 (transmissible gastroenteritis virus : TGEV), 개코로나 바이러스(canine coronavirus : CCoV), 고양이 코로나 바이러스 (feline coronavirus : FCoV), Miniopterus bat(박쥐) coronavirus 1, Miniopterus bat(박쥐) coronavirus HKU8, Rhinolophus bat(박쥐) coronavirus HKU2, Scotophilus bat(박쥐) coronavirus 512, 돼지 혈구 응집성뇌척수염 바이러스(porcine hemagglutinating encephalomyelitis virus : PHEV), 우코로나 바이러스(bovine coronavirus : BCoV), 말코로나 바이러스 (equine coronavirus : EqCoV), 쥐코로나 바이러스(murine coronavirus : MuCoV),Tylonycteris bat(박쥐) coronavirus HKU4, Pipistrellus bat(박쥐) coronavirus HKU5,Rousettus bat(박쥐) coronavirus HKU9, 새코로나 바이러스(Avian coronavirus),흰색 돌고래(Beluga whale)-코로나 바이러스 SW1, 제주직박구리(Bulbul)-코로나 바이러스 HKU11, 개똥지빠귀(Thrush)-코로나 바이러스 HKU12 및 킨바라(Munia)-코로나 바이러스 HKU13로 이루어진 군에서 선택된 어느 하나인 것을 특징으로 하는 약학적 조성물.
- 제1항에 있어서, 상기 자가 복제 감염은 코로나바이러스가 상기 개체의 호흡기 세포에서 복제되어 주변 세포로 감염되는 것임을 특징으로 하는 약학적 조성물.
- 잠재적인 호흡기 바이러스 감염에 노출된 후 호흡기 바이러스에 의한 자가 복제 감염으로부터 개체를 보호하는 노출 후 예방 (PEP) 방법으로서, 상기 방법은 예방적 유효량의 인터페론-베타를 개체에게 투여하는 것임을 특징으로 하는 방법.
- 잠재적인 호흡기 바이러스 감염에 노출된 후 예방적 유효량의 인터페론-베타를 개체에게 투여하는 것을 포함하는 호흡기 바이러스에 의한 자가 복제 감염으로부터 개체를 보호하는 방법.
- 잠재적인 호흡기바이러스 감염에 노출된 개체에서의 호흡기바이러스의 자가 복제 감염 억제용 제제를 제조하기 위한 인터페론-베타의 용도.
- 인터페론-베타를 유효성분으로 포함하는 조성물의 유효량을 이를 필요로 하는 개체에 투여하는 것을 포함하는 잠재적인 호흡기바이러스 감염에 노출된 개체에서의 호흡기바이러스의 자가 복제 감염 억제 방법.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202280017182.6A CN117545500A (zh) | 2021-01-13 | 2022-01-13 | 针对呼吸道病毒的预防性施用方法,包括向潜在的呼吸道病毒感染对象施用干扰素β |
AU2022207315A AU2022207315A1 (en) | 2021-01-13 | 2022-01-13 | Prophylactic administration method against respiratory virus, comprising administering interferon-beta to potential respiratory virus-infected subject |
EP22739735.3A EP4292604A1 (en) | 2021-01-13 | 2022-01-13 | Prophylactic administration method against respiratory virus, comprising administering interferon-beta to potential respiratory virus-infected subject |
JP2023542688A JP2024506803A (ja) | 2021-01-13 | 2022-01-13 | 潜在的な呼吸器ウイルス感染個体にインターフェロンベータを投与することを含む呼吸器ウイルスに対する予防的投与方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2021-0004780 | 2021-01-13 | ||
KR20210004780 | 2021-01-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022154542A1 true WO2022154542A1 (ko) | 2022-07-21 |
Family
ID=82447714
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/000683 WO2022154542A1 (ko) | 2021-01-13 | 2022-01-13 | 잠재적인 호흡기바이러스 감염 개체에 인터페론-베타를 투여하는 것을 포함하는 호흡기바이러스에 대한 예방적 투여 방법 |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP4292604A1 (ko) |
JP (1) | JP2024506803A (ko) |
KR (1) | KR20220102595A (ko) |
CN (1) | CN117545500A (ko) |
AU (1) | AU2022207315A1 (ko) |
WO (1) | WO2022154542A1 (ko) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006527268A (ja) * | 2003-06-09 | 2006-11-30 | ゲノム インスティチュート オブ シンガポール | 臨床的に認められた抗ウイルス剤を用いるsarsコロナウイルス感染の阻害 |
JP2007528890A (ja) * | 2004-03-12 | 2007-10-18 | ユニバーシティ、オブ、サウサンプトン | 呼吸器疾患の抗ウイルス療法のためのインターフェロン−β |
KR101800366B1 (ko) | 2015-07-17 | 2017-11-22 | 서울대학교산학협력단 | 혈장내 유리무세포 DNA(cfDNA)를 이용한 상피세포 성장인자 수용체 유전자 돌연변이 검출용 조성물 및 이를 포함하는 키트 |
KR20190063512A (ko) | 2017-11-30 | 2019-06-10 | 윤현규 | 리얼타임 pcr을 이용한 코로나바이러스 검사 키트 및 방법 |
KR20190071765A (ko) * | 2016-10-21 | 2019-06-24 | 위니베르시테 끌로드 베르나르 리옹 Ⅰ | 코로나 바이러스에 연관된 감염의 치료를 위한 항바이러스 조성물 |
KR102018201B1 (ko) | 2019-05-01 | 2019-09-06 | 대한민국 | 리얼타임 pcr을 이용한 박쥐 유래 코로나바이러스 검사 키트 및 방법 |
KR20200014269A (ko) * | 2017-03-03 | 2020-02-10 | 로욜라 유니버시티 오브 시카고 | 코로나바이러스, 이를 포함하는 백신 및 질병 예방 방법 |
KR20210004780A (ko) | 2019-07-03 | 2021-01-13 | 주식회사 네모이엔지 | 수상 태양광 설비용 부유식 구조물 |
-
2022
- 2022-01-13 WO PCT/KR2022/000683 patent/WO2022154542A1/ko active Application Filing
- 2022-01-13 EP EP22739735.3A patent/EP4292604A1/en active Pending
- 2022-01-13 CN CN202280017182.6A patent/CN117545500A/zh active Pending
- 2022-01-13 KR KR1020220005506A patent/KR20220102595A/ko unknown
- 2022-01-13 JP JP2023542688A patent/JP2024506803A/ja active Pending
- 2022-01-13 AU AU2022207315A patent/AU2022207315A1/en active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006527268A (ja) * | 2003-06-09 | 2006-11-30 | ゲノム インスティチュート オブ シンガポール | 臨床的に認められた抗ウイルス剤を用いるsarsコロナウイルス感染の阻害 |
JP2007528890A (ja) * | 2004-03-12 | 2007-10-18 | ユニバーシティ、オブ、サウサンプトン | 呼吸器疾患の抗ウイルス療法のためのインターフェロン−β |
KR101800366B1 (ko) | 2015-07-17 | 2017-11-22 | 서울대학교산학협력단 | 혈장내 유리무세포 DNA(cfDNA)를 이용한 상피세포 성장인자 수용체 유전자 돌연변이 검출용 조성물 및 이를 포함하는 키트 |
KR20190071765A (ko) * | 2016-10-21 | 2019-06-24 | 위니베르시테 끌로드 베르나르 리옹 Ⅰ | 코로나 바이러스에 연관된 감염의 치료를 위한 항바이러스 조성물 |
KR20200014269A (ko) * | 2017-03-03 | 2020-02-10 | 로욜라 유니버시티 오브 시카고 | 코로나바이러스, 이를 포함하는 백신 및 질병 예방 방법 |
KR20190063512A (ko) | 2017-11-30 | 2019-06-10 | 윤현규 | 리얼타임 pcr을 이용한 코로나바이러스 검사 키트 및 방법 |
KR102018201B1 (ko) | 2019-05-01 | 2019-09-06 | 대한민국 | 리얼타임 pcr을 이용한 박쥐 유래 코로나바이러스 검사 키트 및 방법 |
KR20210004780A (ko) | 2019-07-03 | 2021-01-13 | 주식회사 네모이엔지 | 수상 태양광 설비용 부유식 구조물 |
Non-Patent Citations (5)
Title |
---|
DATABASE PROTEIN 1 December 2020 (2020-12-01), ANONYMOUS : "Chain A, INTERFERON-BETA", XP055950272, retrieved from NCBI Database accession no. 1AU1_A * |
LEE SAEHYUNG, SON WOO SUNG, YANG HO BIN, RAJASEKARAN NIRMAL, KIM SUNG-SU, HONG SUNGYOUL, CHOI JOON-SEOK, CHOI JUN YOUNG, SONG KYOU: "A Glycoengineered Interferon-β Mutein (R27T) Generates Prolonged Signaling by an Altered Receptor-Binding Kinetics", FRONTIERS IN PHARMACOLOGY, vol. 9, XP055950274, DOI: 10.3389/fphar.2018.01568 * |
SINGLETON ET AL., DICTIONARY OF MICROBIOLOGY AND MOLECULAR BIOLOTY, 1994 |
WALKERED: "THE CAMBRIDGE DICTIONARY OF SCIENCE AND TECHNOLOGY", 1988 |
ZHU, NA ET AL.: "A novel coronavirus from patients with pneumonia in China", NEW ENGLAND JOURNAL OF MEDICINE, 2019 |
Also Published As
Publication number | Publication date |
---|---|
AU2022207315A1 (en) | 2023-08-03 |
KR20220102595A (ko) | 2022-07-20 |
EP4292604A1 (en) | 2023-12-20 |
CN117545500A (zh) | 2024-02-09 |
JP2024506803A (ja) | 2024-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2022050516A1 (ko) | 담팔수 추출물을 유효성분으로 포함하는 코로나 바이러스 치료제 | |
WO2021206309A1 (en) | Pharmaceutical composition for prevention or treatment of diseases caused by sars-cov-2 | |
WO2021235616A1 (ko) | 제2형 중증급성호흡기증후군 코로나바이러스 감염 질환의 예방 또는 치료용 조성물 | |
WO2019231220A1 (ko) | 2,3,5-치환된 싸이오펜 화합물의 유방암 예방, 개선 또는 치료 용도 | |
WO2021194290A1 (ko) | 유행성 rna 바이러스 감염질환의 예방 또는 치료용 약제학적 조성물 | |
WO2019225953A2 (ko) | 잣나무 부산물 추출물을 함유하는 헬리코박터파일로리균 제균 효과를 갖는 조성물 | |
WO2022154542A1 (ko) | 잠재적인 호흡기바이러스 감염 개체에 인터페론-베타를 투여하는 것을 포함하는 호흡기바이러스에 대한 예방적 투여 방법 | |
WO2017200192A1 (ko) | 항바이러스 활성을 가지는 사료 첨가제 조성물 | |
WO2021158000A1 (en) | Composition for preventing or treating pulmonary diseases comprising hyaluronan and proteoglycan link protein 1 | |
WO2022173165A1 (ko) | 흑삼을 유효성분으로 포함하는 코로나 바이러스 감염의 예방, 개선 또는 치료용 조성물 | |
WO2019098572A2 (ko) | 간염 바이러스에 의해 유발된 간 섬유화의 개선을 위한 약학 조성물 | |
WO2022131603A1 (ko) | 현초 추출물을 유효성분으로 포함하는 항바이러스 조성물 | |
WO2022045520A1 (ko) | 페난트로인돌리지딘 및 페난트로퀴놀리지딘 알칼로이드 유도체, 이의 광학이성질체, 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 코로나바이러스감염증-19 치료용 조성물 | |
WO2022124525A1 (ko) | 니클로사마이드를 포함하는 근육내 및/또는 피하 투여용 약학적 조성물 | |
KR20230040961A (ko) | 테트란드린 또는 이의 유사체를 포함하는 코로나바이러스 감염 예방 또는 치료용 조성물 | |
WO2022131604A1 (ko) | 상지 유래 화합물을 유효성분으로 포함하는 항바이러스 조성물 | |
WO2021210851A1 (ko) | 태반추출물을 포함하는 항바이러스 조성물 | |
WO2021215616A1 (ko) | 폴리포스페이트를 포함하는 코로나바이러스 감염 또는 감염 질환의 치료용 조성물 | |
WO2021215617A1 (ko) | 폴리포스페이트를 포함하는 코로나바이러스 감염 또는 감염 질환의 예방 또는 소독용 조성물. | |
WO2023059099A1 (ko) | 에제티미브를 유효성분으로 포함하는 폐섬유증의 예방, 개선, 완화 또는 치료용 약학적 조성물 | |
WO2022085806A1 (ko) | 코로나바이러스 감염 질환의 예방 또는 치료용 약학적 조성물 | |
WO2022065971A2 (ko) | 지구자 추출물을 포함하는 코로나바이러스 감염 예방 또는 치료용 조성물 | |
WO2022065983A2 (ko) | 돌외 추출물을 포함하는 코로나바이러스 감염 예방 또는 치료용 조성물 | |
WO2022014813A1 (en) | Pharmaceutical composition for preventing or treating sars-cov-2 infection | |
WO2022065972A2 (ko) | 음양곽 추출물을 포함하는 코로나바이러스 감염 예방 또는 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22739735 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023542688 Country of ref document: JP |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112023013982 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2022207315 Country of ref document: AU Date of ref document: 20220113 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022739735 Country of ref document: EP Effective date: 20230814 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280017182.6 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 112023013982 Country of ref document: BR Kind code of ref document: A2 Effective date: 20230712 |